The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary by Gordon, C et al.
  
The British Society for Rheumatology guidelines for the management of 
systemic lupus erythematosus in adults 
 
Caroline Gordon1,2,3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1,3, Sue Brown4,  Ian N. Bruce5,6,  David 
D'Cruz7, Benjamin Empson8, Bridget Griffiths9 David Jayne10,11, Munther Khamashta12,13, Liz Lightstone14, 
Peter Norton15, Yvonne Norton15, Karen Schreiber,16,17, David Isenberg18 for the British Society for 
Rheumatology Standards, Audit and Guidelines Working Group 
 
1Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental 
Sciences, University of Birmingham, Birmingham, UK  
2Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, 
UK 
3Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK 
4 Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, UK 
5Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute for 
Inflammation and Repair, University of Manchester, Manchester Academic Health Sciences Centre.  
6The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central 
Manchester University Hospitals NHS Foundation Trust, Manchester  UK 
7Louise Coote Lupus Unit, Guy’s Hospital, London, UK 
8Laurie Pike Health Centre, Modality Partnership, Birmingham, UK 
9Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, UK 
10Department of Medicine, University of Cambridge, Cambridge, UK   
11Lupus and Vasculitis Unit, Addenbrooke’s Hospital, Cambridge, UK 
12Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital London UK  
13Division of Women's Health, King's College London, UK. 
14Section of Renal Medicine and Vascular Inflammation, Division of Immunology and Inflammation, 
Department of Medicine, Imperial College London, London, UK 
15LUPUS UK, Romford, Essex, UK 
16Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK   
17Division of Women's Health, King's College London, UK 
18Centre for Rheumatology, University College London, London, UK  
 
Correspondence to: Caroline Gordon, Rheumatology Research Group, Institute of 
Inflammation and Ageing, University of Birmingham Research Laboratories, New Queen 
Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2WB; 
p.c.gordon@bham.ac.uk 
  
Keywords: lupus, diagnosis, assessment, monitoring, management, immunosuppressants, 
treatment, efficacy, non-biologics, biologics 
 
Executive summary 
Scope and purpose of the guideline 
Need for the guideline 
Systemic lupus erythematosus (SLE or lupus) is a complex, multi-system autoimmune disease that 
affects nearly 1 in 1000 people in the UK (1). Despite improvement in survival over the last 40 years, 
lupus patients still die on average 25 years earlier than the mean for women and men in the UK(2).  
General recommendations for the management of lupus have not been published since 2008 although 
European and USA guidelines for lupus nephritis management were published in 2012 (3-5). As the 
disease causes significant morbidity and mortality and can be associated with the rapid accumulation 
of damage, if not promptly diagnosed, regularly monitored and appropriately treated; an up to date 
guideline, consistent with current NHS practice, is warranted to help improve the outcome of this 
disease.  
 
Objectives of the guideline 
To provide comprehensive recommendations,  covering the diagnosis, assessment, monitoring and 
treatment of mild, moderate and severe active lupus disease based on a literature review  (to June 
2015) for non-renal lupus, supplemented as necessary by UK expert opinion and consensus 
agreement, and that do not imply a legal obligation. We also provide a summary of and our strength 




The guidelines have been developed by a multidisciplinary group established by the BSR and 
consisting of academic and NHS consultants in rheumatology and nephrology, rheumatology trainees, 
a general practitioner (GP), a clinical nurse specialist, a patient representative and a lay member. The 
target audience for the guideline includes rheumatologists and other clinicians that care for lupus 
patients such as nephrologists, immunologists, dermatologists, emergency medicine, GPs, trainees, 
clinical nurse specialists, and other allied health professionals. 
 
 
The areas that the guideline does not cover 
  
This guideline does not cover the evidence for topical or systemic therapy for isolated cutaneous 
lupus, nor paediatric lupus. Detailed dosing regimens are beyond the scope of this document. The 
management of complications of lupus including chronic fatigue, thrombosis, cardiovascular risk, 
osteoporosis, infection, and cancer risk are not discussed in detail and should be managed as for 
patients with similar risk factors according to relevant national and international guidelines.  
 
Key recommendations from the guideline  
 
The guideline was developed according to the BSR Protocol for Guidelines. SIGN methodology(6) 
was used to determine levels of evidence (LOE) and grades of recommendations (GOR) for each 
statement and these are shown in brackets below (LOE/GOR). For each recommendation the strength 
of agreement (SOA) of the group was sought on a scale of 1 (no agreement) to 10 (complete 
agreement). The mean percentage agreement was calculated and is shown after each recommendation. 
Treatment strategies are summarized in table 1. The smallest effective dose of corticosteroid should 
be used. More detailed comments about the recommendations, the supporting evidence and cautions 
are provided in the full guideline, available at Rheumatology Online. NICE guidance for use of 
belimumab in active autoantibody-positive SLE in adults has been published 
(https://www.nice.org.uk/guidance/TA397). Reimbursement for rituximab is limited to the NHS 
England 2013 interim clinical commissioning policy statement for rituximab in adult SLE patients 
(https://www.england.nhs.uk/wp-content/uploads/2013/09/a13-psa.pdf ). 
 
Clinical and serological features prompting consideration of diagnosis of SLE  
I. SLE is a multi-system autoimmune disorder. The diagnosis requires a combination of clinical 
features and the presence of at least one relevant immunological abnormality. If there is a 
clinical suspicion of lupus, blood tests including serological markers should be checked. 
(LOE 2++, GOR B, SOA 98%)   
 
II. ANA are present in about 95% of SLE patients.  If the test is negative, there is a low clinical 
probability of the patient having SLE. A positive ANA occurs in approximately 5% of the 
adult population and alone has poor diagnostic value in the absence of clinical features of 
autoimmune rheumatic disease. (2++/ B, SOA 96%) 
 
III. The presence of anti-dsDNA antibodies (2++/B), low complement levels (2++/C) or anti-Sm 
antibodies (2+/C) are highly predictive of a diagnosis of SLE in patients with relevant clinical 
features.  Anti-Ro,/La and anti-RNP  antibodies are less specific markers of SLE (2+/C) as 
they are found in other autoimmune rheumatic disorders as well as SLE (2+/C). (SOA 95%) 
  
 
IV. Antiphospholipid antibodies should be tested in all lupus patients at baseline, especially in 
those with an adverse pregnancy history or arterial/venous thrombotic events (2++/B). 
Confirmatory tests for antiphospholipid syndrome are positive lupus anticoagulant , anti-
cardiolipin antibodies (IgG, IgM) and/or anti-beta-2 glycoprotein-1 (IgG, IgM) on two 
occasions at least 12 weeks apart (2++/B). (SOA 97%) 
 
Assessment of SLE patients  
I. Clinical manifestations in SLE patients may be due to disease activity, damage, drug toxicity 
or the presence of co-morbidity.  In the case of disease activity it is important to ascertain 
whether this is due to active inflammation or thrombosis, as this will define treatment 
strategies. (LOE 2++, GOR B, SOA 97%) 
II. Clinical assessment of a lupus patient should include a thorough history and review of 
systems, full clinical examination and monitoring of vital signs, urinalysis, laboratory tests, 
assessment of health status and quality of life and measurement of disease activity and 
damage using standardised SLE assessment tools (2++/B).  Imaging (4/D), renal (2++/B) and 
other biopsies (4/D) should be performed where indicated. (SOA 100%) 
III. Disease activity is categorised into mild, moderate and severe, with the occurrence of flares 
(2+/C).  Mild disease activity is clinically stable with no life-threatening organ involvement, 
mainly arthritis, mucocutaneous lesions and mild pleuritis. Patients with moderate disease 
activity have more serious manifestations, and severe disease activity is defined as organ or 
life threatening (4/D). (SOA 93%) 
 
Monitoring of SLE  
I. Patients with lupus should be monitored on a regular basis for disease manifestations, drug 
toxicity and comorbidities. (LOE 2++, GOR B, SOA 99%) 
 
II. Those with active disease should be reviewed at least every 1-3 months (2+, C/D) with blood 
pressure (1+/A), urinalysis (1+/A), renal function (1+/A), anti-dsDNA antibodies (2++/B),  
complement levels (2+/C), and CRP (2+/C), full blood count (3/C), and liver function tests 
(4/D) forming part of the assessment and further tests as necessary (4/D). Patients with stable 
low disease activity or in remission can be monitored less frequently eg  6 to 12 monthly 
(4/D). (SOA 99%) 
 
III. The presence of antiphospholipid antibodies is associated with thrombotic events, damage 
and adverse pregnancy outcomes (2++/B).  If previously negative, they should be re-
  
evaluated prior to pregnancy or surgery and in the presence of a new severe manifestation or 
vascular event (4/D). (SOA 96%) 
 
IV. Anti-Ro and La antibodies are associated with neonatal lupus (including congenital heart 
block) and should be checked prior to pregnancy (1+/A). (SOA 100%) 
 
V. Patients with lupus are at increased risk of co-morbidities, such as atherosclerotic disease, 
osteoporosis, avascular necrosis, malignancy and infection (2+/C).  Management of 
modifiable risk factors including hypertension, dyslipidaemia, diabetes, high body mass index 
and smoking should be reviewed at baseline and at least annually (4/D). (SOA 98%) 
 
VI. Immunosuppressive therapy may lead to toxicities. Close monitoring of drugs by regular 
laboratory tests and clinical assessment should be performed in accordance with drug 
monitoring guidelines (4/D). (SOA 98%) 
 
Management of mild SLE  
 
I. Treatments to be considered for the management of mild non-organ threatening disease 
include disease modifying drugs hydroxychloroquine (1++/A) and methotrexate (1+/A), and 
short courses of non-steroidal anti-inflammatory drugs (3/D) for symptomatic control. These 
drugs allow for the avoidance of or dose reduction of corticosteroids. (SOA 94%) 
 
II. Prednisolone treatment at a low dose of up to 7.5mg/day may be required for maintenance 
therapy (2+/C). Topical preparations may be used for cutaneous manifestations and intra-
articular injections for arthritis (4/D). (SOA 93%) 
 
III. High factor UV-A and UV-B sunscreen are important in the management and prevention of 
UV radiation-induced skin lesions (2++/B).  Patients must also be advised about sun 




Management of moderate SLE  
 
I. The management of moderate SLE involves higher doses of prednisolone (up to 0.5 
mg/kg/day) (2+/C), or the use of intramuscular (4/D) or intravenous doses of 
methylprednisolone (2+/C). Immunosuppressive agents are required often to control active 
disease and are steroid-sparing agents (2+/C). They can also reduce the risk of long-term 
damage accrual (4/D).  (SOA 98%) 
 
II. Methotrexate (1+/A), azathioprine (2+/C), mycophenolate mofetil (2++/B), ciclosporin 
(2+/C) and other calcineurin inhibitors (4/D) should be considered in cases of arthritis, 
cutaneous disease, serositis, vasculitis or cytopaenias if hydroxychloroquine is insufficient. 
(SOA 97%) 
 
III. For refractory cases, belimumab (1+/B) or rituximab (2+/C) may be considered. (SOA 98%)  
 
Management of severe SLE  
I. Patients who present with severe SLE including renal and neuropsychiatric manifestations 
need thorough investigation to exclude other aetiologies including infection (4/D). Treatment 
depends on the underlying aetiology (inflammatory and/or thrombotic) and patients should be 
treated accordingly with immunosuppression and/or anticoagulation respectively (4/D). (SOA 
98%) 
 
II. Immunosuppressive regimens for severe active SLE involve IV methylprednisolone (2+/C) or 
high dose oral prednisolone (up to 1 mg/kg/day) (4/D) to induce remission either on their own 
or more often as part of a treatment protocol with another immunosuppressive drug (4/D). 
(SOA 98%) 
 
III. Mycophenolate mofetil or cyclophosphamide are used for most cases of lupus nephritis and 
for refractory severe non-renal disease (2++/B).(SOA 98%)  
IV. Biologic therapies belimumab (1+/B)or rituximab (2+/C) may be considered, on a case-by-
case basis, where patients have failed other immunosuppressive drugs due to inefficacy or 
intolerance. (SOA 98%) 
 
  
Intravenous immunoglobulin (2-/D) and plasmapheresis (3/D) may be considered in patients with 
refractory cytopaenias, thrombotic thrombocytopaenic purpura (1+/B), rapidly deteriorating acute 
confusional state and the catastrophic variant of antiphospholipid syndrome. (SOA 93%) 
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BILAG C scores or 
single B score; SLEDAI 
<6 
Moderate activity/flare 
BILAG 2 or more 





BILAG 1 or more A 
scores; SLEDAI >12 
Typical 
manifestations 
attributed to lupus 
Fatigue, malar rash, 
diffuse alopecia, mouth 
ulcers, arthralgia, 
myalgia, platelets 50-
149 x 109/l 
Fever, lupus related rash 
up to 2/9 body surface 
area, cutaneous 
vasculitis, alopecia with 
scalp inflammation,  
arthritis, pleurisy, 
pericarditis, hepatitis, 
platelets 25-49 x 109/l 
Rash involving >2/9 body 
surface area, myositis, 
severe pleurisy and/or 
pericarditis with effusion, 
ascites, enteritis, 
myelopathy, psychosis, 
acute confusion, optic 
neuritis, platelets <25 x 
109/l 
Initial  
typical drugs and 




preferred or oral 
prednisolone <20mg 
daily for 1-2 weeks  












NSAIDs (for days to 




or IV methyl- 
prednisolone <250mg x 
1-3  
or IM methyl-
prednisolone 80-120mg  
 




















and AZA 2-3 mg/kg/day  
or MMF 2-3 g/day or  

















200 mg/day  
 









Aim to reduce and stop 
drugs except 
hydroxychloroquine 
eventually when in 
stable remission. 
*Prednisolone < 7.5 
mg/day  
 
and AZA 50-100 
mg/day  
or methotrexate 10 
mg/week  
or  








Aim to reduce and stop 
drugs except 
hydroxychloroquine 






MMF 1.0-1.5 g/day or 











Aim to reduce and stop 
drugs except 
hydroxychloroquine 
eventually when in 
stable remission. 
*the lowest effective dose of prednisolone or other corticosteroids should be used at all times.  
 
 
 
